A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Parabilis Medicines, Inc.
Arcus Biosciences, Inc.
Incyte Corporation
Toray Industries, Inc
ImmunityBio, Inc.
AstraZeneca
Endocyte
Sanofi